Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types
文献类型：期刊论文
| 作者 | Hong, Z; Shao, YW (reprint author), Geneseeq Technol Inc, Toronto, ON, Canada.; Shao, YW; Shao, HW; Liang, Y; Chen, J; Zhu, CR; Zhu, LJ; Wang, ZX; Sun, J |
| 刊名 | SCIENTIFIC REPORTS
 |
| 出版日期 | 2017 |
| 卷号 | 7页码:583（1-11） |
| DOI | 10.1038/s41598-017-00520-1 |
| 产权排序 | 8 |
| 文献子类 | Article |
| 英文摘要 | Cancer is a disease of complex genetic alterations, and comprehensive genetic diagnosis is beneficial to match each patient to appropriate therapy. However, acquisition of representative tumor samples is invasive and sometimes impossible. Circulating tumor DNA (ctDNA) is a promising tool to use as a non-invasive biomarker for cancer mutation profiling. Here we implemented targeted next generation sequencing (NGS) with a customized gene panel of 382 cancer-relevant genes on 605 ctDNA samples in multiple cancer types. Overall, tumor-specific mutations were identified in 87% of ctDNA samples, with mutation spectra highly concordant with their matched tumor tissues. 71% of patients had at least one clinically-actionable mutation, 76% of which have suggested drugs approved or in clinical trials. In particular, our study reveals a unique mutation spectrum in Chinese lung cancer patients which could be used to guide treatment decisions and monitor drug-resistant mutations. Taken together, our study demonstrated the feasibility of clinically-useful targeted NGS-based ctDNA mutation profiling to guide treatment decisions in cancer. |
| 学科主题 | Science & Technology - Other Topics |
| 语种 | 英语 |
| 资助机构 | This study was supported by National Natural Science Foundation of China (No. 81302109 to Dr. Yongqian Shu), Geneseeq Technology Inc. Canada, and Nanjing Geneseeq Technology Inc. China. ; National Natural Science Foundation of China [81302109] ; This study was supported by National Natural Science Foundation of China (No. 81302109 to Dr. Yongqian Shu), Geneseeq Technology Inc. Canada, and Nanjing Geneseeq Technology Inc. China. ; National Natural Science Foundation of China [81302109] ; Geneseeq Technology Inc. Canada ; Geneseeq Technology Inc. Canada ; Nanjing Geneseeq Technology Inc. China ; Nanjing Geneseeq Technology Inc. China ; This study was supported by National Natural Science Foundation of China (No. 81302109 to Dr. Yongqian Shu), Geneseeq Technology Inc. Canada, and Nanjing Geneseeq Technology Inc. China. ; National Natural Science Foundation of China [81302109] ; This study was supported by National Natural Science Foundation of China (No. 81302109 to Dr. Yongqian Shu), Geneseeq Technology Inc. Canada, and Nanjing Geneseeq Technology Inc. China. ; National Natural Science Foundation of China [81302109] ; Geneseeq Technology Inc. Canada ; Geneseeq Technology Inc. Canada ; Nanjing Geneseeq Technology Inc. China ; Nanjing Geneseeq Technology Inc. China |
| 源URL | [http://210.75.237.14/handle/351003/29245]  |
| 专题 | 成都生物研究所_天然产物研究 |
| 通讯作者 | Shao, YW (reprint author), Geneseeq Technol Inc, Toronto, ON, Canada. |
| 推荐引用方式 GB/T 7714 | Hong, Z,Shao, YW ,Shao, YW,et al. Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types[J]. SCIENTIFIC REPORTS,2017,7:583（1-11）. |
| APA | Hong, Z.,Shao, YW .,Shao, YW.,Shao, HW.,Liang, Y.,...&Shu, YQ.(2017).Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types.SCIENTIFIC REPORTS,7,583（1-11）. |
| MLA | Hong, Z,et al."Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types".SCIENTIFIC REPORTS 7(2017):583（1-11）. |
入库方式： OAI收割
来源：成都生物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。